Early assessment of MCV to predict clinical outcome in patients with advanced gastrointestinal stromal tumors (GIST) receiving imatinib.
Date
2012Author
![ORCID logo](https://orcid.org/sites/default/files/images/orcid_16x16.png)
Krikelis, Dimitrios
Olmos, David
Scurr, Michelle R.
Jones, Robin Lewis
Ashley, Sue
![ORCID logo](https://orcid.org/sites/default/files/images/orcid_16x16.png)
Source
Journal of Clinical OncologyVolume
30Issue
15Google Scholar check